Developmental pharmacology

Developmental Disabilities Research Reviews

Volumn 16, Issue 3, 2010, Pages 233-238

  van den Anker, Johannes N ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CYP2D6; Developmental pharmacology; Metabolism; Pharmacogenetics; Pharmacokinetics; Psychopharmacology; Renal elimination

Indexed keywords

CAFFEINE; CARBAMAZEPINE; CEFTAZIDIME; CYTOCHROME P450 2D6; DEXAMETHASONE; DRUG METABOLIZING ENZYME; FAMOTIDINE; FLUOXETINE; FLUVOXAMINE; FOSPHENYTOIN SODIUM; LIOTHYRONINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; THEOPHYLLINE; VENLAFAXINE;

DEVELOPMENTAL DISORDER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; DRUG USE; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; ADOLESCENT; AGE; BIOAVAILABILITY; BLOOD; CHILD; DRUG ANTAGONISM; DRUG DETOXIFICATION; DRUG INTERACTION; DRUG MONITORING; DRUG TOXICITY; GENETIC POLYMORPHISM; GENETICS; INFANT; INTESTINE ABSORPTION; METABOLIC CLEARANCE RATE; PHYSIOLOGY; PRESCHOOL CHILD;

ADOLESCENT; AGE FACTORS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP2D6; DEVELOPMENTAL DISABILITIES; DRUG INTERACTIONS; DRUG MONITORING; DRUG TOXICITY; HUMANS; INFANT; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS;

EID: 79952785369     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.122     Document Type: Review

References (43)

1. Allegaert K, van Schaik RH, Vermeersch S, et al. 2008. Postmenstrual age and CYP2D6 polymorphisms determine tramadol O-demethylation in critically ill neonates and infants. Pediatr Res 63:674-679.
2. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332.
3. Aranda JV, Collinge JM, Zinman R, et al. 1979. Maturation of caffeine elimination in infancy. Arch Dis Child 54:946-949.
4. Bajpai M, Roskos LK, Shen DD, et al. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Disp 24:1401-1403.
5. Bartelink IH, Rademaker CM, Schobben AF, et al. 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45:1077-1097.
6. Blake MJ, Gaedigk A, Pearce RE, et al. 2007. Ontogeny of dextromethorphan O- en N-demethylation in the first year of life. Clin Pharmacol Ther 81:510-516.
7. Chen N, Aleksa K, Woodland C, et al. 2006. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 21:160-168.
8. Dahl M-L, Bertilsson L. 1993. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3:61-70.
9. De Hoog M, Mouton JW, Schoemaker RC, et al. 2002. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 71:349-358.
10. De Wildt SN, Kearns GL, Leeder JS, et al. 1999. Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet 36:439-452.
11. De Wildt SN, Kearns GL, Leeder JS, et al. 1999. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485-505.
12. Edginton AN, Schmitt W, Voith B, et al. 2006. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 45:683-704.
13. Gaedigk A, Simon D, Pearce RE, et al. 2007. The CYP2D6 score: translating genotype information into a quantitative measure of phenotype. Clin Pharmacol Ther 83:234-242.
14. Hines RN. 2008. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267.
15. Hines RN, McCarver DG. 2002. The ontogeny of human drugmetabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
16. James LP, Marotti T, Stowe C, et al. 1998. Pharmacokinetics and pharmacodynamics of famotidine in infants. J Clin Pharmacol 38:1089-1095.
17. Johnson TN, Rostami-Hodjegan A, Tucker GT. 2006. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931-956.
18. Kalow W. 1991. Interethnic variation of drug metabolism. Trends Pharmacol Sci 12:102-107.
19. Kearns GL, Abdel-Rahman SM, Alander SW, et al. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167.
20. Kerr BM, Thummel KE, Wurden CJ, et al. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
21. Kinirons MT, O'Shea D, Kim RB, et al. 1999. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66:224-231.
22. Kraus DM, Fischer JH, Reitz SJ, et al. 1993. Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 54:351-359.
23. Krekels EH, van den Anker JN, Baiardi P, et al. 2007. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 8:1787-1799.
24. Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC. 1998. Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 83:2411-2416.
25. Leeder JS. 2003. Developmental and pediatric pharmacogenomics. Pharmacogenomics 4:331-341.
26. Lee der JS, Kearns GL, Spielberg SP, et al. 2010. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol Feb 11. DOI: 10.1177/0091270009360533.
27. Loughnan PM, Greenwald A, Purton WW, et al. 1977. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Arch Dis Child 52:302-309.
28. McCarver DG, Hines RN. 2002. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300:361-366.
29. Milavetz G, Vaughan LM, Weinberger MM, et al. 1986. Evaluation of a scheme for establishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. Disabil Rehabil 109:351-354.
30. Nelson DR, Koymans L, Kamataki T, et al. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
31. Nemeroff CB, DeVane CL, Pollock BG. 1996. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
32. Payne K, Mattheyse FJ, Liedenberg D, et al. 1989. The pharmacokinetics of midazolam in paediatric patients. Eur J Clin Pharmacol 37:267-272.
33. Pynnönen S, Sillanpää M, Frey H, et al. 1977. Carbamazepine and its 10,11-epoxide in children and adults with epilepsy. Eur J Clin Pharmacol 11:129-133.
34. Reed MD. 2008. Team-centered clinical pharmacology practice: is it a remedy for or the basis of our discipline? Clin Pharmacol Ther 83:218-219.
35. Rhodin MM, Anderson BJ, Peters AM, et al. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24:67-76.
36. Riva R, Contin M, Albani F, et al. 1985. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone comedication. Clin Pharmacokin 10:524-531.
37. Shulman RW, Ozdemir V. 1997. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 42 Suppl 1:4S-9S.
38. Stamer UM, Musshoff F, Kobilay M, et al. 2007. Concentrations of tramadol and O-desmethyl-tramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 82:41-47.
39. Stevens JC, Marsh SA, Zaya MJ, et al. 2008. Developmental changes in human liver CYP2D6 expression. Drug Metab Disp 36:1587-93.
40. Van den Anker JN, Hop W, de Groot R, et al. 1994. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 36:578-581.
41. Van den Anker JN, Rakhmanina NY. 2006. Pharmacological research in pediatrics: from neonates to adolescents. Adv Drug Deliv Rev 58:4-14.
42. Van den Anker JN, Schoemaker R, Hop W, et al. 1995. Ceftazidime pharmacokinetics in pre-term infants: effects of renal function and gestational age. Clin Pharmacol Ther 58:650-659.
43. Zanger UM, Raimundo S, Eichelbaum M. 2004. Cytochrome P450 2D6: overview and update on pharmacology, genetics and biochemistry. Naunyn-Schmiedeberg's Arch Pharmacol 369:23-37.